A Study Links A Blood Protein To Memory And Brain Changes In Down Syndrome

TL;DR

For listenersOffer from Amazon

Turn your wind-down time into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

A study of 88 adults with Down syndrome found that higher serum β-synuclein levels were associated with poorer episodic memory and brain changes linked to Alzheimer’s disease. The researchers’ age models suggest the protein’s levels diverged from those in controls well before expected symptoms, but the cross-sectional findings cannot show when changes occur in individuals or what causes them.

A study of 88 adults with Down syndrome found that higher blood levels of the nerve-cell protein β-synuclein were associated with poorer episodic memory and brain imaging patterns linked to Alzheimer’s disease. The findings, published in Alzheimer’s & Dementia, suggest the protein could be studied as an early marker of synaptic changes, but do not establish that it causes those changes or can predict an individual’s future symptoms.

Researchers measured β-synuclein in serum from adults with Down syndrome who had no Alzheimer’s symptoms, prodromal Alzheimer’s, or Alzheimer’s dementia. The groups included 35 people without symptoms, 18 with prodromal disease and 35 with dementia. A comparison group comprised 43 cognitively unimpaired people without Down syndrome. The study was conducted at a single center and analyzed participants at one point in time.

Compared with controls, β-synuclein levels were 1.83 times higher in the group without Alzheimer’s symptoms, 2.82 times higher in the prodromal group and 3.67 times higher in the dementia group. Age-based statistical modeling estimated that levels began to diverge from the control group about 21 years before the expected onset of prodromal Alzheimer’s, and more than seven years before differences in other measured blood markers. These are group-level estimates, not a timeline established for each participant.

Higher β-synuclein was associated with poorer scores on cognitive assessments and with cortical atrophy and reduced glucose metabolism in brain regions vulnerable to Alzheimer’s-related changes. The memory associations varied by disease and intellectual-disability subgroup: findings on some tests were significant only among participants with mild intellectual disability, while an association with delayed recall appeared in both mild and moderate groups. The relationship was not significant for cognitive scores in the dementia group.

A Possible Earlier Signal of Synaptic Change

The study addresses a research need: finding measurable signs of brain changes in adults with Down syndrome, who face an elevated risk of Alzheimer’s disease. A blood test that reflects changes at synapses—the connections between nerve cells—could help researchers track disease-related processes alongside measures of memory and brain imaging. The findings place β-synuclein among candidate research biomarkers, not an established diagnostic test.

The timing suggested by the age model is relevant because the protein’s levels appeared to differ from controls earlier than the other blood markers examined. That may help researchers investigate whether synaptic changes are detectable before changes in markers associated with Alzheimer’s pathology or nerve-fiber damage. But an earlier difference does not by itself show that β-synuclein can identify who will develop dementia, or that using the test would improve care.

Associations with memory and imaging also offer researchers a way to examine whether blood measurements track changes in brain function and structure. The study did not test whether the protein predicts subsequent decline, distinguishes Alzheimer’s from other processes, or should guide clinical decisions. Those questions matter before the result can be applied beyond research.

How the Study Measured Change

Adults with Down syndrome can develop Alzheimer’s-related brain changes, and researchers use cognitive assessments, imaging and biological markers to study their progression. This study compared serum β-synuclein with three other blood measures: p-tau217, associated with Alzheimer’s pathology; GFAP, associated with astroglial changes; and NfL, a marker of nerve-fiber damage. The latter markers were measured in plasma, rather than serum.

Participants completed assessments of dementia symptoms and cognitive performance, including a test of immediate and delayed verbal recall. Researchers also examined MRI scans from 60 participants with Down syndrome and FDG-PET scans from 42. Some participants provided cerebrospinal fluid samples, and the control group was required to have normal core cerebrospinal fluid Alzheimer’s biomarker concentrations.

The paper, titled “Changes in serum β-synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome,” used a cross-sectional design. Its age comparisons model differences among people of different ages; they do not follow the same people over decades. That distinction limits what can be concluded about the order and pace of biological changes in any one person.

“Changes in serum β-synuclein may precede blood-based markers of Alzheimer’s disease pathology among people with Down syndrome.”

— The study authors, as summarized in the report

What the Findings Cannot Establish

Because researchers compared participants at one point in time, the study cannot establish that rising β-synuclein levels precede other changes within the same people. The estimated lead time comes from age modeling across groups, and the expected timing of symptoms is not a forecast for an individual. The researchers also cannot determine from these associations whether β-synuclein reflects trisomy 21-related biology, Alzheimer’s-related synaptic dysfunction, or a combination.

The sample was modest, drawn from a single center, and the imaging analyses covered fewer participants than the blood analyses. The reported memory associations also differed across diagnostic and intellectual-disability groups. It remains unclear how well the results would generalize to broader populations, how levels change over time, and whether the marker adds useful information beyond existing assessments and biomarkers. No clinical threshold or evidence of improved outcomes from testing is reported.

Longitudinal Studies Are Needed

The next step is to test the findings in larger, independent groups and follow participants over time. Repeated blood samples alongside memory assessments, imaging and established Alzheimer’s biomarkers could show whether changes in β-synuclein within an individual track later changes in cognition or brain measures. Researchers would also need to examine whether the marker provides information beyond p-tau217, GFAP and NfL.

The report does not identify a planned follow-up study or a timeline for further results. Until longitudinal and validation studies are available, β-synuclein should be understood as a research measure associated with memory and brain findings in this sample—not as a test that diagnoses Alzheimer’s disease or predicts when symptoms will appear.

Key Questions

What is β-synuclein?

β-synuclein is a protein found at presynaptic nerve-cell connections. Researchers measured it in blood serum to investigate whether it could reflect synaptic changes associated with Alzheimer’s-related processes in adults with Down syndrome.

What did the study find about memory?

Higher serum β-synuclein was associated with poorer performance on some cognitive and episodic-memory measures. The pattern differed across groups: some associations were significant only among people with mild intellectual disability, while the delayed-recall association was reported in mild and moderate groups.

Does the study show that β-synuclein causes memory loss?

No. The study found associations between β-synuclein, memory scores and imaging measures. Its cross-sectional design cannot show that the protein causes cognitive or brain changes, or determine the sequence of changes within an individual.

Can this blood test predict Alzheimer’s disease in a person with Down syndrome?

The study does not establish β-synuclein as a predictive or diagnostic test. The age estimates describe modeled differences between groups, and the report gives no validated clinical threshold or evidence that testing improves care.

What research is needed next?

Larger studies that follow participants over time could assess whether within-person changes in β-synuclein track later memory, imaging or other biomarker changes. Independent validation is also needed to determine whether it adds useful information to existing measures.

Source: rss